GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vascular Solutions Inc (NAS:VASC) » Definitions » Beneish M-Score

Vascular Solutions (Vascular Solutions) Beneish M-Score : 0.00 (As of May. 05, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Vascular Solutions Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Vascular Solutions's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Vascular Solutions was 0.00. The lowest was 0.00. And the median was 0.00.


Vascular Solutions Beneish M-Score Historical Data

The historical data trend for Vascular Solutions's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vascular Solutions Beneish M-Score Chart

Vascular Solutions Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.73 -2.79 -2.84 -2.48 -2.75

Vascular Solutions Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.53 -2.75 -2.29 -2.41 -2.21

Competitive Comparison of Vascular Solutions's Beneish M-Score

For the Medical Devices subindustry, Vascular Solutions's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vascular Solutions's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vascular Solutions's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Vascular Solutions's Beneish M-Score falls into.



Vascular Solutions Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Vascular Solutions for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0759+0.528 * 1.018+0.404 * 1.0526+0.892 * 1.1242+0.115 * 1.0895
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0859+4.679 * -0.005836-0.327 * 0.7311
=-2.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep16) TTM:Last Year (Sep15) TTM:
Total Receivables was $23.0 Mil.
Revenue was 41.773 + 41.187 + 39.378 + 38.085 = $160.4 Mil.
Gross Profit was 26.917 + 26.876 + 25.78 + 25.245 = $104.8 Mil.
Total Current Assets was $89.9 Mil.
Total Assets was $156.6 Mil.
Property, Plant and Equipment(Net PPE) was $41.8 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.6 Mil.
Selling, General, & Admin. Expense(SGA) was $68.6 Mil.
Total Current Liabilities was $14.1 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.
Net Income was 5.44 + 5.403 + -0.255 + 1.557 = $12.1 Mil.
Non Operating Income was 0.022 + 0.032 + 0.016 + -0.045 = $0.0 Mil.
Cash Flow from Operations was 7.555 + 7.234 + -4.335 + 2.58 = $13.0 Mil.
Total Receivables was $19.0 Mil.
Revenue was 36.954 + 37.55 + 34.611 + 33.586 = $142.7 Mil.
Gross Profit was 24.806 + 24.844 + 23.261 + 22.005 = $94.9 Mil.
Total Current Assets was $88.5 Mil.
Total Assets was $143.1 Mil.
Property, Plant and Equipment(Net PPE) was $33.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.8 Mil.
Selling, General, & Admin. Expense(SGA) was $56.2 Mil.
Total Current Liabilities was $17.7 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(22.961 / 160.423) / (18.983 / 142.701)
=0.143128 / 0.133026
=1.0759

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(94.916 / 142.701) / (104.818 / 160.423)
=0.665139 / 0.653385
=1.018

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (89.911 + 41.816) / 156.603) / (1 - (88.469 + 33.068) / 143.138)
=0.158848 / 0.15091
=1.0526

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=160.423 / 142.701
=1.1242

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(5.761 / (5.761 + 33.068)) / (6.592 / (6.592 + 41.816))
=0.148368 / 0.136176
=1.0895

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(68.626 / 160.423) / (56.216 / 142.701)
=0.427782 / 0.393943
=1.0859

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 14.121) / 156.603) / ((0 + 17.653) / 143.138)
=0.090171 / 0.123329
=0.7311

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(12.145 - 0.025 - 13.034) / 156.603
=-0.005836

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Vascular Solutions has a M-score of -2.21 suggests that the company is unlikely to be a manipulator.


Vascular Solutions Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Vascular Solutions's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Vascular Solutions (Vascular Solutions) Business Description

Traded in Other Exchanges
N/A
Address
Vascular Solutions Inc was incorporated in the state of Minnesota in December 1996. It is a medical device company, creates new minimally invasive medical devices, and delivers these products and related services to physicians through its direct domestic sales force and its international distribution network. The Company's products and services are divided into three categories: Catheter products; Hemostat products and Vein products and services. Catheter products consist principally of catheters used in minimally invasive medical procedures for the diagnosis or treatment of vascular conditions, such as the GuideLiner catheter used to access discrete regions of the coronary anatomy and the Pronto extraction catheters used in treating acute myocardial infarction. Hemostat products consist principally of blood clotting products, such as the D-Stat Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets. Vein products and services consist principally of the Vari-Lase endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, and a reprocessing service for the ClosureFAST radiofrequency vein ablation catheter. The Company manufactures its products in its facilities located in the suburbs of Minneapolis, Minnesota and in the country of Ireland. The catheter manufacturing and packaging processes occur under a controlled clean room environment. It purchases components from various suppliers and rely on single sources for several parts of its products. It purchases its requirements for thrombin for use in manufacturing products sold in the U.S. under the Thrombin-JMI Supply Agreement with King. Its main competitors include: Medtronic, Boston Scientific, Covidien, Merit Medical, Marine Polymer Technologies, Cook Medical, Spectranetics, AngioDynamics and Terumo. The Company's products and services are regulated in the United States as medical devices by the FDA under the Federal Food, Drug and Cosmetic Act.
Executives
John L Erb director C/O VASCULAR SOLUTIONS, INC., 6464 SYCAMORE COURT N., MINNEAPOLIS, MN 55369
Richard Nigon director CEDAR POINT CAPITAL, 150 SOUTH 5TH STREET, MINNEAPOLIS MN 55402
Richard W Kramp director 174 STONEBRIDGE ROAD, ST. PAUL MN 55118
Stephens Group Inc 10 percent owner 111 CENTER ST, STE 2300, LITTLE ROCK AR 72201
Paulson J Robert Jr director
Gregg S Sutton officer: VP R&D 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Michael Nagel officer: VP of Sales C/O VASCULAR SOLUTIONS INC, 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Steve Patterson 10 percent owner 111 CENTER STREET STE 2300, LITTLE ROCK AR 72201

Vascular Solutions (Vascular Solutions) Headlines

From GuruFocus

Vascular Solutions Inc. (VASC) CEO Howard Root sells 25,000 Shares

By GuruFocus Research GuruFocus Editor 11-04-2010

Mairs & Power Comments on Vascular Solutions

By Holly LaFon Holly LaFon 12-01-2015

Mario Gabelli Comments on Vascular Solutions

By Holly LaFon Holly LaFon 01-31-2017